From: Kawasaki disease before and during the COVID-19 pandemic: a single-center comparative study in Switzerland
Treatment
Pre-COVID
During COVID
P-value
Number of patients
31
59
IVIG
28 (90.3%)
59 (100%)
0.657
High dose ASA
27 (87.1%)
56 (94.9%)
0.771
Corticosteroids
0 (0.0%)
4 (6.8%)
-